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Bone formation using the process known as minimodeling
forms only lamellar bone in the absence of prior bone
resorption even in uremic patients. In patients undergoing
parathyroidectomy for secondary hyperparathyroidism, we
compared the contribution of minimodeling to remodeling
during the change in bone volume. Iliac bone biopsies were
used to measure parameters related to minimodeling and
remodeling before, at 3 to 4 weeks and 10 to 12 weeks after
parathyroidectomy. Osteoblast surface due to minimodeling
was greater than the entire bone osteoblast surface before
and at 10 to 12 weeks after parathyroidectomy, but not 3 to
4 weeks after surgery. Minimodeling significantly increased
osteoid volume 3 to 4 weeks after parathyroidectomy. The
rate of change of osteoid volume by minimodeling was
greater than that of osteoid volume during the first 3 to
4 weeks after surgery, indicating osteoid formation was
more active at the minimodeling surface than at the entire
bone surface. Furthermore, higher mineral apposition rates
at the minimodeling sites than at remodeling sites yielded
increased minimodeling bone volume at 10 to 12 weeks
after surgery. Our results show that bone formation by
minimodeling is more active than by remodeling and
accounts, in part, for the increase of bone volume following
parathyroidectomy.
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Bone formation is sometimes seen in the absence of previous
bone resorption, a process referred to as minimodeling.1,2
Previous reports have related the cancellous minimodeling
observed in uremic patients with hypoparathyroidism to
direct activation of osteoblasts3 (Yajima A, Ogawa Y,
Tominaga Y et al. Minimodeling in chronic and postpara-
thyroidectomy hypoparathyroidism. J Am Soc Nephrol 2004;
15: 511A (abstract)). In the process of minimodeling, bone
formation occurs from a quiescent surface,3,4 and the
resultant newly formed bone is normal lamellar in texture.1–4
As it has been reported that bone volume (BV)-referent
minimodeling BV (Ml.BV) (Ml.BV/BV) in cancellous bone is
greater in uremic patients with secondary hyperparathyroid-
ism than in nonuremic subjects, minimodeling might reduce
the rate of bone loss in these patients.4 Minimodeling
surface (Ml.S)-referent osteoblast surface (Ob.S) (Ob.S/Ml.S)
is reported to be greater than the entire bone surface
(BS)-referent osteoblast surface (Ob.S/BS) in patients with
secondary hyperparathyroidism,4 indicating that bone form-
ation is more active at the minimodeling sites in these
patients. Ml.BV/BV is reported to be greater in uremic
patients with hypoparathyroidism than in those with
secondary hyperparathyroidism,3 suggesting that Ml.BV/BV
might increase markedly after treatment for secondary
hyperparathyroidism. Although the mean BV at minimodel-
ing sites is reported to account for less than 1% of the
trabecular BV, and minimodeling sites were less than 2%,
on average, of the entire cancellous bone surface, the mean
osteoid volume at sites of minimodeling accounts for
approximately 10% of the entire osteoid volume, and the
labeled surfaces at minimodeling sites constitute approxi-
mately 25–50%, on average, of the entire labeled surface in
healthy individuals.2 These results suggest that minimodeling
seems to be important in new bone formation. Therefore, we
investigated changes of the relative osteoid volume associated
with minimodeling in comparison with those associated with
remodeling after parathyroidectomy. We also conducted
tetracycline-based analysis of the dynamic parameters at the
minimodeling sites as compared with those at the remodeling
sites. Thus, we investigated the contribution of minimodeling
to the formation of new bone after parathyroidectomy in
patients with secondary hyperparathyroidism.
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RESULTS
Serum bone metabolic markers
Serum intact parathyroid hormone (iPTH) levels decreased
at 3–4 weeks after parathyroidectomy (as measured in Group
I, n¼ 15) and the suppression was sustained until 10–12
weeks (as measured in Group II, n¼ 7). Serum levels of bone
resorption markers, including tartrate-resistant acid phos-
phatase and deoxypyridinoline, decreased significantly at 3–4
weeks after parathyroidectomy, and the decreases were
sustained until 10–12 weeks. Serum levels of bone formation
markers, including carboxy-terminal propeptide of type I
procollagen (PICP) and total alkaline phosphatase (total
ALP), showed a temporary but significant increase at 3–4
weeks after parathyroidectomy (Group I), as reported
previously,5 although 10–12 weeks after surgery, a tendency
toward decrease of the serum PICP and significant decrease
of the serum total ALP was observed (Group II). No
significant changes were observed in the serum calcium (Ca)
levels at either 3–4 or 10–12 weeks after parathyroidectomy,
probably because of the initiation of oral administration of
alfacalcidol (1a-hydroxyvitamin D3; Chugai Pharmaceutical
Co. Ltd, Tokyo, Japan) at doses of 0.5–2.0 mg/day with
intravenous Ca gluconate or oral Ca carbonate. Serum
phosphorus (P) levels were significantly decreased at 3–4
weeks after parathyroidectomy (Group I), but not at 10–12
weeks (Group II) (Table 1).
Bone histomorphometry
The remodeling and minimodeling parameters were also
measured both before and at 3–4 weeks (Group I) and at
10–12 weeks (Group II) after parathyroidectomy. The
histomorphometric parameters, including (1) osteoclast
surface (Oc.S/BS), (2) eroded surface (ES/BS), (3) fibrosis
volume (Fb.V/TV), (4) osteoblast surface (Ob.S/BS), (5)
osteoid volume (OV/BV), (6) osteoid surface (OS/BS), and
(7) osteoid thickness (O.Th), were measured at the entire
bone surface, including the sites of remodeling and those of
minimodeling.6 The histomorphometric parameters of bone
resorption, including Oc.S/BS, ES/BS and Fb.V/TV, which
were extremely high before parathyroidectomy, decreased
significantly at 3–4 weeks after surgery. Ob.S/BS had already
decreased at 3–4 weeks after parathyroidectomy in Group I,
although we previously reported a temporary increase of
Ob.S/BS at 1 week after parathyroidectomy.5,7 The decrease
was sustained until 10–12 weeks after surgery. The other
parameters of bone formation, including OV/BV and OS/BS,
which were also markedly increased before parathyroidect-
omy, showed further increase at 3–4 weeks, and the
increases were sustained until 10–12 weeks after surgery
(Tables 2 and 3).
In terms of the static minimodeling parameters, signifi-
cant decrease of Ob.S/Ml.S was observed at 3–4 weeks after
parathyroidectomy and the decrease remained sustained until
Table 1 | Serum bone metabolic markers before (A) and at 3–4 weeks after (B) parathyroidectomy (n=15), and those before (A)0
and at 10–12 weeks after (C) surgery (n=7)
iPTH TRAP DPD PICP Total ALP Ca P
(pg/ml) (U/l) (pmol/ml) (ng/ml) (U/l) (mg/100 ml) (mg/100 ml)
(A) 1229.6±447.1 23.5±8.9 48.4±43.3 265.1±79.8 725.2±492.4 10.0±0.9 5.2±1.5
(B) 26.7±13.7 7.3±3.0 9.8±4.2 699.5±450.8 1027.0±540.2 11.1±1.8 2.9±1.7
P-value Po0.001 Po0.001 Po0.001 P=0.005 Po0.001 P=0.099 P=0.004
(A)0 1395.4±812.3 24.6±9.4 76.0±98.8 540.3±681.0 1023.9±641.0 9.7±1.1 5.4±1.7
(C) 31.0±21.6 10.6±5.0 7.4±2.9 199.3±109.5 355.1±112.3 8.6±1.6 3.8±1.5
P-value P=0.028 P=0.028 P=0.028 P=0.063 P=0.028 P=0.063 P=0.076
Normal range 10-65 5.5-17.2 unknown 30-182 85-255 8.4-10.4 2.5-4.5
Ca, calcium; DPD, deoxypyridinoline; iPTH, intact parathyroid hormone; P, phosphorus; PICP, carboxy-terminal propeptide of type I procollagen; total ALP, total alkaline
phosphatase; TRAP, tartrate-resistant acid phosphatase.
The differences in the serum levels of the bone metabolic markers between (A) and (B) and between (A)0 and (C) were analyzed by Wilcoxon’s matched pairs test.
Values are expressed as mean±s.d.
Table 2 | Static histomorphometric variables before (A) and at 3–4 weeks after (B) parathyroidectomy in Group I (n=15), and
those before (A)0 and at 10–12 weeks after (C) surgery (n=7) were measured
Oc.S/BS ES/BS Fb.V/TV OS/BS O.Th
(%) (%) (%) (%) (lm)
(A) 4.5±3.8 27.0±10.6 5.8±4.8 52.8±18.3 14.3±7.6
(B) 0.1±0.5 1.8±1.5 0.6±1.4 83.0±16.4 20.0±9.1
P-value 0.001 0.001 0.001 0.001 0.001
(A)0 3.8±2.9 26.1±10.4 7.5±8.2 51.9±19.2 14.3±5.4
(C) 0.2±0.4 4.0±2.2 0.6±1.7 80.4±19.1 22.9±13.2
P-value 0.028 0.028 0.028 0.028 0.052
Normal range 0.7±0.7 4.0±2.0 0 14.3±6.3 9.3±2.1
ES/BS, eroded surface; Fb.V/TV, fibrosis volume; Oc.S/BS, osteoclast surface; OS/BS, osteoid surface; O.Th, osteoid thickness.
The differences in the histomorphometric variables between (A) and (B) and between (A)0 and (C) were analyzed by Wilcoxon’s matched pairs test.
Values are expressed as mean±s.d.
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10–12 weeks after surgery. Ob.S/Ml.S was significantly greater
than Ob.S/BS before parathyroidectomy (48.0±25.1 vs
20.8±9.9%, P¼ 0.002) (Group I), but not at 3–4 weeks after
parathyroidectomy (12.6±12.2 vs 14.3±12.6%, P¼ 0.532)
(Group I), although Ob.S/Ml.S was greater than Ob.S/BS
again at 10–12 weeks (7.1±5.8 vs 1.2±1.6%, P¼ 0.028)
(Group II) (Table 3). Although type II osteoblasts were most
abundant at the minimodeling sites before parathyroi-
dectomy, a greater abundance of type IV osteoblasts was
found at these sites at 3–4 weeks and at 10–12 weeks after
parathyroidectomy.
Osteoid seams associated with the minimodeling sites
were lamellar,2,4 but those at the remodeling sites were a
mixture of woven and lamellar osteoid seams (Figure 1).7,8
Significant increase of Ml.BV-referent minimodeling
osteoid volume (Ml.OV/Ml.BV) from 14.21±7.47 before
parathyroidectomy to 42.00±8.36% (Po0.001) was ob-
served during the first 3–4 weeks after parathyroidectomy,
whereas no significant change of Ml.BV/BV was observed at
this time point in Group I (2.00±1.20 before parathyroi-
dectomy vs 2.57±2.10% at 3–4 weeks after parathyroi-
dectomy: P¼ 0.427) (Table 3). Ml.OV/Ml.BV was greater
than OV/BV at 3–4 weeks after parathyroidectomy (42.00±
8.36 vs 19.02±9.39%, P¼ 0.001). To elucidate the important
contribution of minimodeling-mediated bone formation to
the total increase of BV after parathyroidectomy, the rate
of changes of OV/BV (DOV/BV) was compared with that
of Ml.OV/Ml.BV (DMl.OV/Ml.BV) during the first 3–4 weeks
after parathyroidectomy. DMl.OV/Ml.BV was greater than
DOV/BV (3.22±1.46 vs 2.16±1.52, P¼ 0.020), indicating
that osteoid formation at the minimodeling sites was greater
than that at the entire bone surface. No significant difference
Table 3 | Static histomorphometric variables, including OV/BV, Ob.S/BS, and minimodeling-related parameters before (A) and
at 3–4 weeks after (B) parathyroidectomy (n=15), and those before (A)0 and at 10–12 weeks after (C) surgery (n=7)
Ml.BV/TV Ml.BV/BV OV/BV Ml.OV/BV Ml.OV/Ml.BV Ob.S/BS Ob.S/Ml.S
(%) (%) (%) (%) (%) (%) (%)
(A) 0.43±0.30 2.00±1.20 12.29±9.75 0.29±0.23 14.21±7.47 20.8±9.9 48.0±25.1
(B) 0.64±0.64 2.57±2.10 19.02±9.39 1.04±0.79 42.00±8.36 14.3±12.6 12.6±12.2
P-value 0.221 0.427 0.011 0.002 o 0.001 0.031 o 0.001
(A)0 0.50±0.38 2.14±1.72 13.21±9.38 0.27±0.23 12.87±2.49 20.7±12.2 43.7±20.9
(C) 2.38±1.23 9.47±4.18 22.0±16.05 2.76±3.37 18.63±15.58 1.2±1.6 7.1±5.8
P-value 0.028 0.028 0.028 0.028 0.345 0.028 0.028
Normal range Unknown 0.64±1.10 1.9±1.1 0.15±0.33 21.5±8.1 4.4±3.2 Unknown
Ml.BV/TV, tissue volume-referent minimodeling bone volume; Ml.BV/BV, bone volume-referent minimodeling bone volume; Ml.OV/BV, bone volume-referent minimodeling
osteoid volume; Ml.OV/Ml.BV, minimodeling bone volume-referent minimodeling osteoid volume; Ob.S/BS, osteoblast surface; Ob.S/Ml.S, minimodeling surface-referent
osteoblast surface; OV/BV, osteoid volume.
The differences in the histomorphometric variables between (A) and (B) and between (A)0 and (C) were analyzed by Wilcoxon’s matched pairs test.







Figure 1 | Tetracycline labeling at 4 weeks after parathyroidectomy at the sites of remodeling and minimodeling. Single and vague
labeling was seen more frequently at the sites of remodeling, associated with a scalloped cement line indicating previous bone resorption.
Double and clear labeling was seen more frequently at the sites of minimodeling. These were not associated with a scalloped cement
line, indicating the absence of previous bone resorption.
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between DMl.OV/Ml.BV and DOV/BV (1.54±1.44 vs
1.75±1.37, P¼ 0.612) was found during 12 weeks after
parathyroidectomy. In terms of the dynamic parameters,
mineral apposition rate (MAR) was compared between the
sites of minimodeling and those of remodeling after
parathyroidectomy. Only slight double-labeling could be
observed on cancellous surface at both the sites of remodeling
and minimodeling. Among the 13 patients of Group I in
whom tetracycline was administered at 3–4 weeks after
parathyroidectomy, double-labeling was found in only seven
patients, with only single-labeling in the remaining six
patients. MAR and BS-referent bone formation rate
(BFR/BS) were decreased and single-labelings were abundant
after parathyroidectomy.9 But because mineralization was
not sustained even in patients with only single-labeling, we
measured MAR and BFR/BS, as indicated in Materials and
Methods. When MAR and BFR/BS were measured separately
at the sites of remodeling and minimodeling, MAR was
greater at the minimodeling sites than at the remodeling
sites (0.467±0.179 vs 0.307±0.177mm/day, P¼ 0.003) after
parathyroidectomy, which is concomitant with the more
frequent double-labeling at the minimodeling sites than that
at the remodeling sites (Table 4; Figure 1). In contrast to
MAR, BFR/BS was not greater at the minimodeling sites than
at the remodeling sites (0.008±0.009 vs 0.012±0.009 mm3/
mm2/year, P¼ 0.142), as BS-referent labeled surface (LS/BS)
was greater in the latter than in the former (18.9±9.7 vs
7.4±5.0%, P¼ 0.004). Analyzed in further detail, BS-referent
single-labeled surface was greater at the remodeling sites
than at the minimodeling sites (18.0±9.5 vs 6.3±4.4%,
P¼ 0.003), whereas no significant difference of BS-referent
double-labeled surface was observed between the remodeling
and minimodeling sites (0.9±1.7 vs 1.1±1.6%, P¼ 0.611).
But the ratio of BS-referent double-labeled surface to LS/BS
was greater at the minimodeling sites than at the remodeling
sites in all the seven patients in whom double labeling was
found. The observation of seven bone biopsy specimens
taken at 10–12 weeks after parathyroidectomy revealed a
significant increase of Ml.BV/BV from 2.14±1.72 to
9.47±4.18% (P¼ 0.028) at the minimodeling sites (Table 3).
DISCUSSION
By conducting serial bone biopsies before and after
parathyroidectomy, we examined the contribution of bone
formation by minimodeling to the increase of bone mineral
density, in comparison with that of remodeling. We
compared the changes of Ob.S/Ml.S with those of Ob.S/BS
after parathyroidectomy to assess the importance of mini-
modeling-mediated bone formation in these patients. Before
parathyroidectomy, Ob.S/Ml.S was greater than Ob.S/BS. The
number of type II and type III osteoblasts increased at 1 week
after parathyroidectomy at the entire bone surface,7 leading
to a further increase of osteoid tissue. Ml.OV/Ml.BV was
greater than OV/BV at 3–4 weeks after parathyroiderctomy,
and DMl.OV/Ml.BV was also greater than DOV/BV during
the first 3–4 weeks after surgery, indicating that osteoid
formation was activated to a great degree at the mini-
modeling sites than at the remodeling sites after parathy-
roidectomy. Osteoid formation by type II and type III
osteoblasts appeared to be more active at the minimodeling
sites,7,10 because these osteoblasts, which play important roles in
the formation of osteoid tissue, are abundant at the mini-
modeling sites before parathyroidectomy. However, by 4 weeks
after parathyroidectomy, Ob.S/Ml.S decreased to the level
comparable with Ob.S/BS, as reflected by the abrupt decrease
in the number of active type II and type III osteoblasts.7 In turn,
the number of flattened (type IV) osteoblasts, which play
important roles in bone mineralization,10 was increased at
3–4 weeks after surgery more at the minimodeling sites.
Although Ml.OV/Ml.BV was greater than OV/BV at
3–4 weeks after parathyroidectomy (P¼ 0.001), MAR was
significantly greater at the minimodeling sites than at the
remodeling sites. Therefore, the amount of osteoid seams
mineralized by 12 weeks after surgery would be greater at the
minimodeling sites than at the remodeling sites, explaining
the significant increase of Ml.BV/BV during the 12 weeks
after parathyroidectomy. The greater gain of mineralized
BV at minimodeling sites is considered to be caused by
the greater MAR attributable to the increase of type IV
osteoblasts at both 3–4 weeks and 10–12 weeks after
parathyroidectomy, with the result that there was no
difference between Ml.OV/Ml.BV and OV/BV at 10–12 weeks
after parathyroidectomy (P¼ 0.237). Owing to the absence of
bone resorption, greater increase of osteoid volume, and
greater MAR at the minimodeling sites (Tables 2–4), the
increase of mineralized BV at the minimodeling sites, in part,
contributed to the increase of bone mineral density after
parathyroidectomy even though LS/BS was significantly small
(Table 4). As the normal ranges of bone histomorphometric
parameters might differ depending on the gender, ethnicity
Table 4 | Dynamic parameters, including MAR, sLS/BS, dLS/BS, LS/BS, and BFR/BS values at the sites of remodeling and
minimodeling at 3–4 weeks after parathyroidectomy (n=13)
MAR (lm/day) sLS/BS (%) dLS/BS (%) LS/BS (%) BFR/BS (mm3/mm2/year)
Remodeling site 0.307±0.177 18.0±9.5 0.9±1.7 18.9±9.7 0.012±0.009
Minimodeling site 0.467±0.179 6.3±4.4 1.1±1.6 7.4±5.0 0.008±0.009
P-value 0.003 0.003 0.611 0.004 0.142
BFR/BS, bone surface-referent bone formation rate; dLS/BS, bone surface-referent double labeled surface; LS/BS, bone surface-referent labeled surface; MAR, mineral
apposition rate; sLS/BS, bone surface-referent single labeled surface.
The differences in the dynamic parameters between the sites of remodeling and those of minimodeling were analyzed by Wilcoxon’s matched pairs test.
Values expressed as mean±s.d.
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and race,6 one of the limitations of this study is that the
normal ranges of histomorphometric parameters except for
minimodeling parameters used in this study represent those
for postmenopausal Caucasian female11,12 and Caucasian
male13 subjects, but not for Japanese subjects.
An increase of osteoid formation early after parathyroi-
dectomy was followed by the relatively rapid mineralization
at the minimodeling sites as compared with mineralization
at the remodeling sites, as MAR at the minimodeling sites
was greater than that at the remodeling sites. In addition,
Ob.S/Ml.S was again higher than Ob.S/BS at 10–12 weeks
after surgery, probably because of the sustained decrease
in the serum PTH.3 As LS/BS at the minimodeling sites was
extremely small, BFR/BS at the minimodeling sites was not
greater than that at the remodeling sites. Thus, an increased
minimodeling volume in patients in the hypoparathyroid
state following parathyroidectomy might, in part, contribute
to the increase of lamellar BV as well as that of total BV
after parathyroidectomy. It would have been of interest to
measure bone mineral density before and at 10–12 weeks after
parathyroidectomy to determine if there were any further
gains in bone mass during this interval. In addition, because
minimodeling is associated with the formation of lamellar
bone alone, it may, in part, contribute to the reduction of
fracture risk after parathyroidectomy in patients with
secondary hyperparathyroidism.14
Exercise is important in the maintenance of minimodeling
in cancellous bone, as evidenced by the reported relation
between an adequate exercise and an increase of mini-
modeling volume.3 The patients enrolled in this study
began to walk and exercise from the day after parathy-
roidectomy. When unilateral compression loads on a
hollow diaphysis increase sufficiently to strain the bone
surface, formation drifts associated with modeling in
cortical bone expand the outside diameter of bone.4 If the
compression loads were transmitted to cancellous bone,
minimodeling in cancellous bone would also be enhanced.
However, the type and intensity of exercise that might induce
an increase of minimodeling volume have not been
investigated yet.
Although hyperparathyroid bone disease begins with stage
3 chronic kidney disease,15 some studies have shown that the
reduction of bone mineral density in renal dysfunction is not
as severe as that estimated from the degree of increase of
serum PTH.16 The present results, together with the previous
reports, indicated that minimodeling BV is greater in uremic
patients than in normal individuals,2–4 suggesting that bone
formation by minimodeling might attenuate the rate of bone
loss caused by renal dysfunction.
In conclusion, bone formation, including osteoid forma-
tion and bone mineralization, was more active at the
minimodeling sites than at the remodeling sites after
parathyroidectomy in patients with secondary hyperpar-
athyroidism, suggesting that minimodeling-mediated bone




Sixteen hemodialysis patients (9 males, 7 females) suffering from
severe secondary hyperparathyroidism underwent parathyroidect-
omy and sequential iliac bone biopsies before and after parathy-
roidectomy. The mean age of the patients was 56.6±9.2 (39–71)
years, with a mean hemodialysis duration of 13.6±7.9 (1–25) years.
The causes of the renal failure in the patients were chronic
glomerulonephritis (n¼ 10), polycystic kidney disease (n¼ 1), and
unknown causes (n¼ 5), but none of the patients suffered from
diabetes mellitus. Body mass index of the patients was 20.7±2.6
(17.3–25.8) kg/m2. Bone histomorphometric data were evaluated in
11 patients in our previous study (data not shown),5 and an
additional five patients were recruited for this study. The condition
was refractory to conservative therapy with intravenous calcitriol
(1a,25-dihydroxyvitamin D3; Kirin Brewery Co. Ltd, Tokyo, Japan),
maxacalcitriol (22 oxa-1a-dihydroxyvitamin D3; Chugai Pharma-
ceutical Co. Ltd, Tokyo, Japan) or falecalcitol (26,26,26,27,27,27-
hexafluoro-1,25-dihydroxyvitamin D3; Taisho Pharmaceutical Co.
Ltd, Tokyo, Japan) in all the patients, or the patients suffered from
increased soft-tissue calcification resulting from persistent elevation
of the Ca P product. The use of these medications, therefore, was
suspended at 2 months before parathyroidectomy to avoid the
surgical complications arising from the prolonged hypercalcemia
and/or hyperphosphatemia. In addition, as the effects of Ca and/or
P levels on minimodeling have not yet been clarified, these
parameters were relatively stable to the extent possible, and the
mean value of CaP products was below 70 (mg/100 ml)2 at the
time of parathyroidectomy. Serum iPTH levels were 1262.3±478.0
(770–2180) pg/ml and the CaP product was 54.6±18.2
(21.9–84.2) (mg/100 ml)2. In addition, the patients who had led a
sedentary life were excluded because of the possible effect of physical
activity on minimodeling.3,4 The use of medications known to
influence the bone metabolism was limited to Ca carbonate before
parathyroidectomy. The Ca concentration in the dialysis water was
2.5 mEq/l. The patients were divided into two groups as follows:
Group I (n¼ 15) and Group II (n¼ 7)—of the 16 patients, bone
biopsy was conducted before and at 3–4 (mean; 3.8±0.4) weeks
after parathyroidectomy in 15 patients (Group I). Six out of 15
patients in Group I underwent a third biopsy at 12 weeks after
surgery (Group II). An additional patient who underwent bone
biopsy before and at 10 weeks after parathyroidectomy was added to
these six patients. Thus, Group II had a total of seven patients who
underwent bone biopsy before and at 10–12 (mean; 11.7±0.8)
weeks after surgery.
Informed consent was obtained from all the patients after an
explanation was provided about both the risks and the outcomes of
the bone biopsies and of parathyroidectomy. The Institutional
Review Board of Towa Hospital and its affiliated hospital approved
of the consent form.
Serum bone metabolic parameters
Serum iPTH (Allegro intact PTH, Nichols Institute Diagnostics,
San Clemente, CA, USA) was measured by an immunoradiometric
assay,17 whereas the serum level of deoxypyridinoline (Metra DPD,
Quidel Corporation, San Diego, CA, USA) was measured by an
enzymeimmunoassay18 and tartrate-resistant acid phosphatase
was measured by colorimetry using nitrophenyl phosphatase as
the substrate.5 Serum total ALP was measured by colorimetry using
nitrophenyl phosphate as the substrate,19 and PICP was mea-
sured by radioimmunoassay (PICP ORION, ORION Diagnostica,
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Espoo, Finland).20 Serum Ca and P levels as well as the serum
markers of bone metabolism were measured before and at the time
of the second bone biopsy, 3–4 weeks after parathyroidectomy in
Group I and 10–12 weeks after parathyroidectomy in Group II. The
differences in the serum levels of bone metabolic markers measured
before and after parathyroidectomy, that is, 3–4 weeks (Group I,
n¼ 15) and 10–12 weeks (Group II, n¼ 7) after parathyroidectomy
are shown in Table 1.
Parathyroidectomy
Four or five parathyroid glands were successfully removed under the
general anesthesia in most patients and 150 mg of diffuse
hyperplastic parathyroid tissue was cut into pieces measuring about
1 mm in diameter and autotransplanted into the adipose tissue of
the abdominal wall in the 15 patients.5,7,9 Serum iPTH levels in these
patients fell to 25 pg/ml or less by 1 week after parathyroidectomy.
In one patient of Group I, because only three parathyroid glands
could be removed, 50 mg instead of 150 mg of parathyroid tissue was
autotransplanted, in case one parathyroid gland might have been left
unresected. Serum iPTH level in this patient was 212 pg/ml at 1
week and fell to 76 pg/ml at 4 weeks after parathyroidectomy. No
surgical complications, including obvious infection such as
pneumonia, bacterial infection at the site of neck surgery, blood
loss exceeding 50 ml from the wound, or cardiovascular events, were
encountered in any patients.
Bone histomorphometry
Transiliac bone biopsy to measure the bone histomorphometric
parameters was performed from the left iliac crest before
parathyroidectomy and from the right iliac crest at 3–4 weeks after
parathyroidectomy (Group I). In Group II, bone biopsy specimens
were obtained from the left iliac crest before parathyroidectomy at
10–12 weeks after surgery.
Each bone biopsy specimen was obtained using a trephine (8 mm
in inner diameter), fixed in ethanol and stained by the Villanueva
method. The histomorphometric dynamic parameters including MAR
and BFR/BS were measured at 3–4 weeks after parathyroidectomy in 13
of the 15 patients of Group I because these 13 patients gave us the
informed consent for tetracycline administration. Before the second
biopsy, tetracycline hydrochloride for labeling was administered for
labeling according to the 3, 10, 3, 4 or 5 day schedule.9 Bone
histomorphometric analysis was performed by direct tracing using a
digitizer.4 Histomorphometric parameters were calculated with a
computer software (Histomorphometric System, System Supply Co.
Ltd., Ina, Japan). A single experienced investigator (Akemi Ito)
measured the parameters in each specimen. When histomorphometic
analysis was performed by Akemi Ito on 2 specimens for 7 consecutive
days to test the reproducibility, the variance of each histomorphometric
parameter (BV/TV, OS/BS, BFR/BV) was 0.8–10.8%, which was
considerably smaller than that reported previously.21 The results of
the bone histomorphometric analysis were expressed according to the
methods of Parfitt et al.6
The sites of bone formation were classified into those of
remodeling and minimodeling sites. Remodeling sites were
identified based on the presence of a scalloped cement line
indicating previous bone resorption. Minimodeling sites were
identified based on the formation of mineralized bone in the




Mean tetracycline-labeling thickness (mcm)
Total duration of tetracycline administration (day)
= mineral apposition rate (mcm/day) = mineral apposition rate (mcm/day)
Distance between the central points of the labelings (mcm)
The first duration without tetracyclin administration (day)
Figure 2 | Measurement of MAR in patients with double labeling and only single labeling. Method to calculate MAR in patients with
only single labeling (left figure); the mean of labeled thickness (mm) was divided by the total duration of tetracycline administration (day).
Tetracycline hydrochloride (Japan Lederle, Tokyo, Japan) was administered orally for labeling according to the following schedule:
tetracycline hydrochloride for 3 days, no agent for 10 days, tetracycline for another 3 days, and no agent for 4 or 5 days. Method to calculate
MAR in patients with double labeling (right figure). The distance between the central point of each labeling (mm) was divided by the
first duration without tetracycline administration (day). The first duration without tetracycline was 10 days in this patient.
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(not scalloped) and associated with a quiescent surface on the
marrow side.1–4 The bone formed by minimodeling had a normal
lamellar architecture, resembling the adjacent underlying bone. The
dividing line between the new bone formed by minimodeling and
old bone is known as the ‘lamellar separation’. Lamellar bone can be
easily detected by microscopy using polarized light.2 The following
bone histomorphometric parameters were calculated: (1) BV/TV,
(2) Oc.S/BS, (3) ES/BS, (4) Fb.V/TV, (5) Ob.S/BS, (6) OV/BV, (7)
OS/BS, (8) O.Th, (9) Ob.S/Ml.S, (10) Ml.OV/Ml.BV, (11) Ml.OV/
BV, (12) Ml.BV/BV, (13) TV-referent Ml.BV (Ml.BV/TV).2–4,6 MAR,
as a dynamic parameter, was also measured. When tetracycline
double-labeling was seen, the distance between the central points of
the two labelings was divided by the first duration of suspension of
the tetracycline administration. When only single clear or vague
labeling could be observed, labeled thickness (L.Th; mm) of the
single labeling was divided by the sum of the scheduled duration
(namely the first duration of tetracycline administration, the first
duration of suspension of tetracycline administration, the second
duration of tetracycline administration, and the second duration of
suspension of tetracycline administration), to calculate MAR
(Figure 2). Both MAR and BFR/BS were measured only after
parathyroidectomy to determine the relative contributions of both
remodeling and minimodeling to the increase of the mineralized BV
after parathyroidectomy. The normal values of Tables 2 and 3 were
obtained from the previous reports.2,12
Statistical analyses
Variables of bone remodeling and minimodeling measured before
and after parathyroidectomy were compared (Tables 2 and 3). The
values of Ml.OV/Ml.BV and OV/BV measured after parathyroidec-
tomy were divided by those measured before parathyroidectomy to
obtain DMl.OV/Ml.BV and DOV/BV; then, the statistical signifi-
cance of the difference between DMl.OV/Ml.BV and DOV/BV was
investigated. In addition, the statistical significance of the differences
in the dynamic parameters between the remodeling sites and the
minimodeling sites was also investigated (Table 4). Statistical
analyses were performed by the Wilcoxon’s matched pairs test.
Differences were considered significant at Po0.05.
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